Literature DB >> 32923904

Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.

Marina Kushnirsky1, Lynn G Feun2,3, Sakir H Gultekin4, Macarena I de la Fuente1,2.   

Abstract

Entities:  

Year:  2020        PMID： 32923904      PMCID： PMC7446525          DOI： 10.1200/PO.19.00272

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  28 in total

1.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Authors:  Genevieve Schindler; David Capper; Jochen Meyer; Wibke Janzarik; Heymut Omran; Christel Herold-Mende; Kirsten Schmieder; Pieter Wesseling; Christian Mawrin; Martin Hasselblatt; David N Louis; Andrey Korshunov; Stefan Pfister; Christian Hartmann; Werner Paulus; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2011-01-29       Impact factor: 17.088

2.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Authors:  Paolo A Ascierto; Grant A McArthur; Brigitte Dréno; Victoria Atkinson; Gabrielle Liszkay; Anna Maria Di Giacomo; Mario Mandalà; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Caroline Dutriaux; Claus Garbe; Yibing Yan; Matthew Wongchenko; Ilsung Chang; Jessie J Hsu; Daniel O Koralek; Isabelle Rooney; Antoni Ribas; James Larkin
Journal:  Lancet Oncol       Date:  2016-07-30       Impact factor: 41.316

3.  Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

Authors:  Christiane B Knobbe; Julia Reifenberger; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2004-10-28       Impact factor: 17.088

Review 4.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

5.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Authors:  Kevin B Kim; Richard Kefford; Anna C Pavlick; Jeffrey R Infante; Antoni Ribas; Jeffrey A Sosman; Leslie A Fecher; Michael Millward; Grant A McArthur; Patrick Hwu; Rene Gonzalez; Patrick A Ott; Georgina V Long; Olivia S Gardner; Daniele Ouellet; Yanmei Xu; Douglas J DeMarini; Ngocdiep T Le; Kiran Patel; Karl D Lewis
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

6.  Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?

Authors:  Sanda Alexandrescu; Andrey Korshunov; Siang Hui Lai; Salma Dabiri; Sushama Patil; Rong Li; Chie-Schin Shih; Jose M Bonnin; Jonathan A Baker; Emma Du; David W Scharnhorst; David Samuel; David W Ellison; Arie Perry
Journal:  Brain Pathol       Date:  2015-09-22       Impact factor: 6.508

7.  Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.

Authors:  Andrey Korshunov; Lukas Chavez; Tanvi Sharma; Marina Ryzhova; Daniel Schrimpf; Damian Stichel; David Capper; Dominik Sturm; Marcel Kool; Antje Habel; Bette K Kleinschmidt-DeMasters; Marc Rosenblum; Oksana Absalyamova; Andrey Golanov; Peter Lichter; Stefan M Pfister; David T W Jones; Arie Perry; Andreas von Deimling
Journal:  Brain Pathol       Date:  2017-10-30       Impact factor: 6.508

8.  Profile of vemurafenib-induced severe skin toxicities.

Authors:  L Peuvrel; G Quéreux; M Saint-Jean; A Brocard; J M Nguyen; A Khammari; A C Knol; E Varey; B Dréno
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-11-02       Impact factor: 6.166

9.  Dabrafenib and trametinib in BRAFV600E mutated glioma.

Authors:  Nicholas F Brown; Thomas Carter; Neil Kitchen; Paul Mulholland
Journal:  CNS Oncol       Date:  2017-10-06

10.  Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Authors:  G V Long; K T Flaherty; D Stroyakovskiy; H Gogas; E Levchenko; F de Braud; J Larkin; C Garbe; T Jouary; A Hauschild; V Chiarion-Sileni; C Lebbe; M Mandalà; M Millward; A Arance; I Bondarenko; J B A G Haanen; J Hansson; J Utikal; V Ferraresi; P Mohr; V Probachai; D Schadendorf; P Nathan; C Robert; A Ribas; M A Davies; S R Lane; J J Legos; B Mookerjee; J-J Grob
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976
View more
  5 in total

1.  Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.

Authors:  Mary Jane Lim-Fat; Kun Wei Song; J Bryan Iorgulescu; Brian M Andersen; Deborah A Forst; Justin T Jordan; Elizabeth R Gerstner; David A Reardon; Patrick Y Wen; Isabel Arrillaga-Romany
Journal:  J Neurooncol       Date:  2021-03-01       Impact factor: 4.130

Review 2.  An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5.

Authors:  Tamara Lah Turnšek; Xuanmao Jiao; Metka Novak; Sriharsha Jammula; Gina Cicero; Anthony W Ashton; David Joyce; Richard G Pestell
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

3.  Allogeneic Natural Killer and Cytomegalovirus (CMV)-pp65 Pulsed Dendritic Cells Induced Complete Response Through 15 Months in a Patient with Recurrent Glioblastoma: A Case Study.

Authors:  Serhat Gumrukcu; Tung X Nguyen; Rachel L White; Gregory T Howell; Phillip Musikanth
Journal:  Am J Case Rep       Date:  2021-03-31

4.  Abnormal Schwannoma-like Growth of multiple, multifocal BRAF V600E-positive Glioblastoma in the Interior Acoustic Canal with Leptomeningeal Infiltration: a case report.

Authors:  Roopa Jayarama-Naidu; Evelyn Gallus
Journal:  J Med Case Rep       Date:  2022-02-08

5.  Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI.

Authors:  Xiaomin Cai; Zheng Chen; Bowen Chang; Ming Tu; Shiting Li; Xuhui Wang; Ming Chen
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.